Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15181483 | 1.00 | DPP4 (0.44) | DPP4F2CYP2D6KMT2ASCN4A | |
| SCHEMBL858 | 0.81 | CYP2D6 (0.42) | CYP2D6KMT2AIDO1TDO2HTR2A | |
| Hydrochloric Acid SCHEMBL10708013 | 0.79 | HTT (0.44) | CYP2D6KMT2AIDO1TDO2HTR2A | |
| SCHEMBL10257436 | 0.78 | IDO1 (0.48) | IDO1TDO2 | |
| SCHEMBL27584562 | 0.77 | CFTR (0.44) | — | |
| SCHEMBL3955535 | 0.76 | CYP2D6 (0.42) | DPP4F2CYP2D6KMT2AGLS | |
| Cyclopropane SCHEMBL28325005 | 0.76 | CYP2D6 (0.38) | CYP2D6KMT2AIDO1TDO2GLS | |
| SCHEMBL17294114 | 0.75 | ADRA2A (0.44) | DPP4F2CYP2D6KMT2ATAAR1 | |
| SCHEMBL6686071 | 0.75 | ADRA2A (0.44) | DPP4F2CYP2D6KMT2ATAAR1 | |
| SCHEMBL5517002 | 0.74 | CYP2D6 (0.41) | DPP4F2CYP2D6KMT2AGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1223959-B1 | INHIBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | US GOV HEALTH & HUMAN SERV (US) | 2007-05-23 | — | — | EP | claimed |
| US-7132392-B1 | Inhibition of cell motility and angiogenesis by inhibitors of Grb2-SH2-domain | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-11-07 | — | — | US | claimed |
| EP-1223959-A2 | INHBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-07-24 | — | — | EP | claimed |
| EP-1163262-A1 | PHENYLALANINE DERIVATIVES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2001028577-A2 | INHIBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-04-26 | — | — | WO | claimed |
| WO-2000056760-A1 | PHENYLALANINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-09-28 | — | — | WO | claimed |
| US-20200289662-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2020-09-17 | — | — | US | disclosed |
| US-10583197-B2 | Antibody-active agent conjugates and methods of use | LEGOCHEM BIOSCIENCES, INC. (KR) | 2020-03-10 | — | — | US | disclosed |
| EP-3610889-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | LegoChem Biosciences, Inc. (KR) | 2020-02-19 | — | — | EP | disclosed |
| EP-2707031-B1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | LEGOCHEM BIOSCIENCES INC (KR) | 2019-06-26 | — | — | EP | disclosed |
| US-20180021451-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LIGACHEM BIOSCIENCES INC. (KR) | 2018-01-25 | — | — | US | disclosed |
| US-9669107-B2 | Antibody-active agent conjugates and methods of use | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-06 | — | — | US | disclosed |
| US-20170014410-A1 | TREATMENT OF PROLIFERATIVE DISORDERS WITH A CHEMILUMINESCENT AGENT | SEMOREX TECHNOLOGIES LTD. (IL) | 2017-01-19 | — | — | US | disclosed |
| EP-1223959-B1 | INHIBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | US GOV HEALTH & HUMAN SERV (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20070042966-A1 | Inhibition of cell motility, angiogenesis, and metastasis | Gov't of the USA, represented by the Secretary, Dep't of Health and Human Services (US) | 2007-02-22 | — | — | US | disclosed |
| US-7132392-B1 | Inhibition of cell motility and angiogenesis by inhibitors of Grb2-SH2-domain | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1223959-A2 | INHBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1163262-A1 | PHENYLALANINE DERIVATIVES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001028577-A2 | INHIBITION OF CELL MOTILITY AND ANGIOGENESIS BY INHIBITORS OF THE GRB2 SH2-DOMAIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2000056760-A1 | PHENYLALANINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289662-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FCGRT, CD47, FNTA | DPP4 1627/4885F2 4509/4885CYP2D6 4488/4885 |
| US-10583197-B2 | Antibody-active agent conjugates and methods of use | FNTA, FCGRT, CD47 | DPP4 1645/4885F2 4447/4885CYP2D6 4426/4885 |
| US-20070042966-A1 | Inhibition of cell motility, angiogenesis, and metastasis | HGF, HDGF, MET | DPP4 726/4885F2 2210/4885CYP2D6 4772/4885 |
| US-20170014410-A1 | TREATMENT OF PROLIFERATIVE DISORDERS WITH A CHEMILUMINESCENT AGENT | CCNY, MKI67, CCNA1 | DPP4 4172/4885F2 1237/4885CYP2D6 1838/4885 |
| US-20180021451-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FCGRT, CD47, FNTA | DPP4 1627/4885F2 4509/4885CYP2D6 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.